Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Mundipharma
Femme et Homme
Entre 2 ans et 18 ans
Mundipharma
MAJ Il y a 4 ans
MUNDIPHARMA BCX1777-108 : Essai de phase 1-2 évaluant la tolérance puis l'efficacité de différents doses de forodesine, chez des patients jeunes ayant un lymphome non hodgkinien à cellules T ou une leucémie aiguë lymphoblastique à cellules B ou T. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase I/II pharmacokinetic study of intravenous and oral forodesine in children with relapsed or refractory T-cell or B-cell precursor acute lymphoblastic leukaemia or T-cell non-hodgkin's lymphoma.
Pays
France
Organes
Leucémies aiguës
,
Lymphomes non hodgkinien
Spécialités
Chimiothérapie
,
Pédiatrie
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Research Ltd
MAJ Il y a 4 ans
A phase II prospective non-comparative multicenter clinical trial to determine the efficacy and safety of intrathecal liposomal cytarabine (DepoCyte®) in preventing CNS-relapse in patients with aggressive Non-Hodgkin-Lymphomas at risk for CNS metastasis
Incidence of confirmed leptomeningeal metastasis (CNS relapse) during the post treatment observation period of one year verified by CNS cytology
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Research GmbH & Co. KG
MAJ Il y a 4 ans
A study to demonstrate the improvement in symptoms of constipation in subjects with cancer on non-cancer related pain requiring round the clock opioid therapy
1. To demonstrate that subjects taking OXN PR have improvement in symptoms of constipation as measured by the Bowel Function Index (BFI) compared to subjects taking OxyPR. 2. To demonstrate non-infer...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Research GmbH & Co. KG
MAJ Il y a 4 ans
A randomised, double-blind, active-controlled, double-dummy, parallel group study to determine the safety and efficacy of oxycodone / naloxone prolonged release tablets in subjects with moderate to severe, chronic cancer pain
To determine the improvement in symptoms of constipation in subjects receiving treatment with oxycodone/naloxone prolonged release tablets (OXN) compared to subjects receiving oxycodone prolonged rele...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Partly by Mundipharma Pharmaceuticals BV (Netherlands)
MAJ Il y a 4 ans
Onset of analgesia with OxyNorm Instant in healthy volunteers
Background and study aims Acute and breakthrough pain (sudden additional acute pain on top of the long-term pain) is difficult to treat, especially since the pain requires immediate relief. Various dr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Research GmbH & Co. KG
MAJ Il y a 4 ans
Efficacy and Safety in a randomised acute pain study of MR308
To demonstrate the efficacy of MR308 doses in the Treatment of acute moderate to severe pain. Efficacy will be assessed by showing superiority of MR308 doses over Placebo and non-inferiority compared ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Research GmbH & Co. KG
MAJ Il y a 4 ans
A study to evaluate the effect and tolerability of laxatives (medicines against constipation) for the reversal of constipation caused by opioids (medicines against pain)
Primary Objective •To assess the effect of SLT on the frequency of soft (stool of type 3, 4 or 5 on the Bristol Stool Form Scale (BSFS)) complete bowel movements (SCBMs) per week in subjects taking W...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Pharmaceuticals B.V
MAJ Il y a 4 ans
A clinical study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission. Een klinische studie om de concentratie Remsima™ (infliximab biosimilar) in het bloed te onderzoeken nadat patiënten met de ziekte van Crohn, Colitis Ulcerosa of Reumatoïde Artritis in remissie zijn omgeschakeld van Remicade (infliximab)
To demonstrate that the infliximab serum concentration of Remsima™ is non-inferior to the infliximab serum concentration of Remicade , 16 weeks after switch from Remicade to Remsima™ in subjects with ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma China Ltd
MAJ Il y a 4 ans
Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment
To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA) in the pain relieving treatment during 48h postoperative period, by comparing with morphine i.v. P...
Pays
China
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma OY
MAJ Il y a 4 ans
A randomised, double-blind, parallel group multicenter study to demonstrate non-inferiority of the analgesic efficacy of oxycodone/naloxone 10/5 or 20/10 mg prolonged release tablets (OXN PR) BID compared to oxycodone 10 or 20 mg prolonged release tablets (OXY PR) BID in subjects with postoperative pain after knee arthroplasty
• To demonstrate that treatment with OXN PR tablets is non-inferior to treatment with OXY PR tablets in terms of analgesic efficacy in patients with postoperative pain after knee arthroplasty based on...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
Suivant